Patent application number | Description | Published |
20080221018 | Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto - The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate. | 09-11-2008 |
20090247744 | HYDROFORMYLATION PROCESS FOR PHARMACEUTICAL INTERMEDIATE - The invention relates to an improved process for the preparation of an advanced synthetic intermediate of ACE inhibitors. In one aspect, the present invention is based on a novel process for the preparation of an aldehyde of formula (I), wherein (N) | 10-01-2009 |
20090281359 | PROCESS FOR OLEFIN ETHERIFICATION - The invention relates to processes for the etherification of olefins with alcohols. According to one aspect, a heterogeneous etherification catalyst is used under conditions that permit limiting the contact time between the desired product and the catalyst, thereby mitigation reverse reactions. According to a second aspect, a recycling process is used that significantly increases the yield of desired product. | 11-12-2009 |
20100041160 | ANALYSIS OF HIGH MOLECULAR WEIGHT MPEG ALCOHOL COMPOSITIONS - The invention is directed toward novel high molecular weight and high purity mPEG alcohol compositions as well as a process for obtaining said compositions by removing PEG diols from the mPEG alcohol after polymerization is complete. | 02-18-2010 |
20110009675 | Process for the Continuous Production of High Purity Phenolic Glycol Ether - Phenolic glycol ethers, e.g., ethylene glycol phenyl ether, are prepared by a continuous, nonaqueous process comprising the steps of (A) contacting under isothermal reactive conditions in a first reactor or reaction zone an alkylene oxide, e.g., ethylene oxide, with (i) a stoichiometric molar excess of a phenolic compound, e.g., phenol, and (ii) a catalytic amount of a base, e.g., sodium hydroxide, homogeneously dispersed throughout the phenolic compound, to form a first intermediate phenolic glycol ether product, (Bj transferring the first intermediate phenolic glycol ether product to a second reactor or reaction zone, and (C) subjecting the first intermediate phenolic glycol ether product to adiabatic reactive conditions in the second reactor or reaction zone to form a second intermediate phenolic glycol ether product comprising phenolic glycol ether, unreacted phenolic compound, catalyst, water and byproduct glycols. In addition, the mono-/di-product weight ratio can be adjusted by increasing or decreasing the amount of base catalyst employed. | 01-13-2011 |
20110015111 | SULFONATE SURFACTANTS AND METHODS OF PREPARATION AND USE - Provided are new anionic surfactants and methods of their preparation and use. The surfactants are compounds of the formula I: | 01-20-2011 |
20110105507 | VINYL ETHER COMPOUNDS AND METHODS OF THEIR PREPARATION AND USE - Provided are new functionalized surfactants and methods of their preparation and use. The surfactants are compounds of formula I: | 05-05-2011 |
20110112328 | Difunctional, Amine-Based Surfactants, and Their Precursors, Preparation, Compositions and Use - Cationic surfactants of formula I | 05-12-2011 |
20120078008 | Process for Reducing Inorganics from and Concentrating Anionic Surfactant Solutions - A process including contacting one or more Strecker sulfonation reaction products of one or more halogenated alkyl ethers in the presence of sulfite with one or more polar water soluble organic solvents selected from acetone, methyl ethyl ketone, the C | 03-29-2012 |
20120232303 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto - The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate. | 09-13-2012 |
20130253229 | APPARATUS AND PROCESS FOR USING OLEFIN AS AN AZEOTROPIC ENTRAINER FOR ISOLATING 1,3-DICHLORO-2-PROPANOL FROM A 2,2'-OXYBIS (1-CHLOROPROPANE) WASTE STREAM - Disclosed are a process and an apparatus for using an olefin as an azeotropic entrainer to isolate a target organic compound from a waste stream. The olefin may be, for example, 1-decene, 1-dodecene, or 1-tetradecene. The target organic compound may be 1,3-dichloro-2-propanol in waste stream comprising a 2,2′-oxybis(1-chloropropane). | 09-26-2013 |
20140024852 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto - The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate. | 01-23-2014 |
20140054223 | Process for Reducing Inorganics from Anionic Surfactant Solutions - A process comprising contacting deionized water with one or more Strecker sulfonation reaction products of one or more halogenated alkyl ethers in the presence of sulfite, wherein the one or more Strecker sulfonation reaction products each comprise one or more inorganic salts on a dry basis and one or more surfactant components, form a filtration mixture; loading the filtration mixture into a high pressure filtration system containing a membrane having a membrane molecular weight cutoff allowing preferential passage of the inorganic salts, for example, of greater than or equal to 200 Daltons; wherein the high pressure filtration system is operated at a pressure greater than ambient pressure and is configured to cause crossflow of the filtration mixture along a surface of the membrane resulting in a permeate solution which substantially passes through the membrane and a retentate solution which substantially does not pass through the membrane; wherein the permeate comprises less than or equal to 15 weight percent surfactant component, based on the weight of the filtration mixture is provided. | 02-27-2014 |